Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Cour Pharmaceuticals Development Company Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners, which indicates that each pending matter is under the review of a different patent office official. This distribution requires the applicant to manage three separate sets of examiner expectations and timelines.
The prosecution activity is also spread across 3 distinct art units, suggesting that the company's pharmaceutical developments fall into three different regulatory categories. PARK, HAEJIN S is the busiest examiner for this portfolio and is currently overseeing 1 busiest examiner pending office action. This examiner is responsible for 1 of the 3 pending office actions currently active.
Strategic management of the 3 pending office actions requires a focus on the individual requirements of the 3 distinct art units. Because there is no overlap among the 3 distinct examiners, the applicant cannot rely on a single prosecution strategy. Instead, the company must tailor its responses to the specific feedback of each examiner, including the 1 busiest examiner pending action assigned to PARK, HAEJIN S.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18333103 | PARTICLES ENCAPSULATING FUSION PROTEINS CONTAINING LINKED EPITOPES | ROSENTHAL, ANDREW S | 84d overdue |
| 18713321 | PREPARATION OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF PEANUT ALLERGY | PARK, HAEJIN S | — |
| 18702114 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | BUNNER, BRIDGET E | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1647 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713321 | PREPARATION OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF PEANUT ALLERGY | PARK, HAEJIN S | 1614 | §103DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18702114 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES | BUNNER, BRIDGET E | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18333103 | PARTICLES ENCAPSULATING FUSION PROTEINS CONTAINING LINKED EPITOPES | ROSENTHAL, ANDREW S | 1613 | §103DP | Final Rejection | 84d overdue | Pending | Jun 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCour Pharmaceuticals Development Company Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Haejin S Park has the most, with 1 of Cour Pharmaceuticals Development Company Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
